- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02941328
SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4 (SPACE)
A Phase II, Mono-center, Placebo-controlled, Double-blind, Crossover Trial to Investigate Effect and Efficacy of Pyridostigmine in Dutch Patients With Spinal Muscular Atrophy Types 2, 3 and 4
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this cross-over trial we will investigate the effects of pyridostigmine (mestinon) versus a placebo on fatigability in patients with hereditary proximal spinal muscular atrophy (SMA) types 2, 3 and 4 (aged 12 and older) The study participants will be using a placebo during 8 weeks and mestinon during 8 weeks. Both investigators and patients are blinded to the treatment allocation in both periods. Patients will be randomly assigned to use placebo or mestinon first. At the end of the study, patients will have used both mestinon and a placebo during 8 weeks.
In both phases (periods) of the cross over study, study medication dosage will slowly be increased to a maximum dosage of 6 mg/kg/day (spread over 4 doses daily) in order to either prevent side effects or to manage them as good as possible. This scheme allows us to assist our participants in case side effects do occur early. Although we strive to have all patients on the same dosage per kg of body weight, serious side effects will obviously lead to lowering the dosage.
Before the start of medication use (either placebo or pyridostigmine), baseline measurements will be taken: a physical examination and data concerning both primary and secondary outcomes (MFM, MRC scores, fatigability tests, etc.) will be collected. After use a drug (mestinon/placebo) for 8 weeks these tests will be repeated, to evaluate possible medication effect. After a wash-out period of approximately 1-2 weeks the same scheme is used for the second study period (i.e. the cross-over design). Unblinding follows after the entire study is completed (i.e.: last included patients finishes participation).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- University Medical Center of Utrecht (UMCU)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A clinical diagnosis of SMA type 2, 3a, 3b or 4
- Genetically confirmed homozygous SMN1 deletion
- Ability to complete visits during trial period;
- Given oral and written informed consent when ≥18 years old;
- Given informed consent by the parents or legal representative(s) in case of patients aged ≥12 till <18 years old (in accordance with Dutch law)
- Ability of performing at least 2 subsequent rounds of the Nine Hole Peg test
- A maximum total Motor Function Measure (MFM) score of 80% (i.e.: a maximum score under 80% of the D1+D2+D3 subscores).
Exclusion Criteria:
- Known concomitant disorders of the NMJ (e.g. but not limited to: Lambert Eaton myasthenic syndrome, myasthenia gravis);
- Use of drugs that may alter NMJ function
- Classic SMA type 1;
- Apprehension against participation in EMG;
- Inability to meet study visits;
- Mechanical gastro-intestinal, urinary or biliary obstruction;
- Clinical significant alterations of laboratory tests (electrolytes, liver function, kidney function, thyroid function or blood dysplasia) drawn within 14 days prior to start of study entry;
- ECG abnormalities known as a contraindication for pyridostigmine use;
- Current pregnancy or breast-feeding
- Allergy to bromides
- Severe bronchial asthma (in case of uncertainty of diagnosis, we will contact treating pulmonologist or physician)
- Total MFM score at baseline (screening) > 80% (i.e.: a maximum total MFM score above 80% of the D1+D2+D3 subscores).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pyridostigmine
(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods.
Both investigators and participants are blinded for what medication is used in what period.
All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
|
Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
Other Names:
|
Placebo Comparator: Placebo
(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods.
Both investigators and participants are blinded for what medication is used in what period.
All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
|
Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MFM (Motor Function Measurement).
Time Frame: change over the course of 8 weeks compared to baseline
|
D1+D2+D3 but also D1, D2, or D3 sub scores of the MFM scales will be used.
|
change over the course of 8 weeks compared to baseline
|
repeated nine-hole peg test performance
Time Frame: Change in performance (in time to complete) the test rounds over the course of 8 weeks of medication compared to baseline
|
The time needed tot complete multiple rounds of the nine hole peg test (hence: repeated NHPT) will be recorded (visit 1) and compared to the performance on the test after 8 weeks of treatment (placebo or mestinon) (visit 2).
Visit 3 will serve as the baseline measurement for the 2nd study period (again followed by 8 weeks of treatment and the final study visit (visit 4)).
|
Change in performance (in time to complete) the test rounds over the course of 8 weeks of medication compared to baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
endurance nine hole peg test
Time Frame: Change in performance after 8 weeks of therapy (placebo or mestinon).
|
During the endurance tests, patients will perform at 75% of their maximum performance.
Differences in before and after treatment results (number of rounds completed) will be analysed
|
Change in performance after 8 weeks of therapy (placebo or mestinon).
|
endurance box-and-block test
Time Frame: Change in performance after 8 weeks of therapy (placebo or mestinon)
|
During the endurance tests, patients will perform at 75% of their maximum performance.
Differences in before and after treatment results (number of rounds completed) will be analysed.
This test will be performed only if the patient is capable of performing it.
|
Change in performance after 8 weeks of therapy (placebo or mestinon)
|
endurance walk test
Time Frame: Change in performance after 8 weeks of therapy (placebo or mestinon).
|
During the endurance tests, patients will perform at 75% of their maximum performance.
Differences in before and after treatment results (e.d.
total distance travelled) will be analysed.
This test will be performed only if the patient is able to walk.
|
Change in performance after 8 weeks of therapy (placebo or mestinon).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: W.L. Van der Pol, MD, PhD, UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Motor Neuron Disease
- Muscular Atrophy
- Atrophy
- Muscular Atrophy, Spinal
- Spinal Muscular Atrophies of Childhood
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Cholinesterase Inhibitors
- Pyridostigmine Bromide
Other Study ID Numbers
- NL38048.041.14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Muscular Atrophy
-
Marco CapogrossoRoche-GenentechRecruitingSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Novartis Gene TherapiesActive, not recruitingSMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type IIIUnited States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
-
Hoffmann-La RocheRecruitingSpinal Muscular Atrophy (SMA)Belgium, United States, Croatia, Japan, Netherlands, Spain, Canada, Poland, United Kingdom, Italy, Portugal, Australia
-
Northwell HealthCompletedAdult Spinal Muscular AtrophyUnited States
-
Hugh McMillanFamilies of Spinal Muscular Atrophy; Gwendolyn Strong FoundationTerminatedSpinal Muscular Atrophy (SMA)Canada
-
Hoffmann-La RocheAssociation Française contre les Myopathies (AFM), ParisCompletedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type III Non AmbulantGermany, Italy, France, Belgium, Poland, Netherlands, United Kingdom
-
AveXis, Inc.United BioSource, LLCRecruitingSpinal Muscular Atrophy (SMA)Japan, United States, Korea, Republic of, Israel, Greece, Ireland, Portugal, Russian Federation, Taiwan
-
Istanbul Medipol University HospitalIstanbul UniversityRecruitingNeuromuscular Diseases | Spinal Muscular Atrophy Type 3Turkey
Clinical Trials on Pyridostigmine
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedDiabetes Mellitus | Constipation | Gastric Emptying | Colonic TransitUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPostural Tachycardia SyndromeUnited States
-
Ain Shams UniversityCompletedPostdural Puncture HeadacheEgypt
-
Hospital de Clinicas de Porto AlegreCompletedDiabetes ComplicationsBrazil
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
University of MiamiAmerican Diabetes AssociationCompleted
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
University of AarhusAarhus University HospitalUnknownMyasthenia GravisDenmark
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHIV | Non-HIV | Vagus Nerve DysfunctionUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)Suspended